cdc25c

BN82002 (CDC25 Phosphatase Inhibitor I) 是一种CDC25 phosphatase 家族的有效的、不可逆的、选择性的泛抑制剂。它显示出比 CD45 酪氨酸磷酸酶高约 20 倍的选择性。

M2N12 是一种高度选择性的细胞分裂周期蛋白磷酸酶 25C 抑制剂，IC50值为 0.09 μM。它还抑制 Cdc25A 和 Cdc25B 的活性，IC50值分别为 0.53 μM 和 1.39 μM。它具有抗肿瘤活性，可研究癌症。

DA-3003-1 (DA-3003-1) 是一种可渗透进细胞膜且具有有效性和选择性的 Cdc25 dual specificity phosphatase 抑制剂，具有抗肿瘤活性，对 Cdc25B2、Cdc25A、Cdc25B2 和 Cdc25C具有抑制作用。

BN82002 hydrochloride是一种CDC25磷酸酶抑制剂，在体外抑制重组人CDC25A、B和C的磷酸酶活性，阻滞细胞周期，降低肿瘤在小鼠体内的生长速度。

NSC305787 hydrochloride ((Rac)-NSC305787 hydrochloride) 是一种可透过细胞膜且具有选择性和有效性的小分子 Cdc25 dual specificity phosphatase 和 EZR 双重抑制剂，在胰腺癌细胞中显示出抗肿瘤活性，对Cdc25B2， Cdc25A，Cdc25B2 和 Cdc25C 具有抑制作用。NSC 663284 抑制 NSD2 (IC50 of 170 nM) 酶的活性。

SB-218078 is less potently inhibits Cdc2 (IC50: 250 nM) and PKC (IC50: 1000 nM). SB-218078 is a potent, ATP-competitive, and cell-permeable checkpoint kinase 1 inhibitor that inhibits Chk1 phosphorylation of cdc25C (IC50: 15 nM).

Inhibitor #2714是一种新型细胞增殖抑制剂，有效阻滞G2 M期，降低磷酸化的cell division cycle 25C (Cdc25C)水平，并增强p53表达。该化合物在体外能够抑制肺癌细胞的增殖和血管生成，并诱导凋亡。

CBP501 is a peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2 cyclin B, preventing entry into the mitotic phase of the cell cycle.

NSC 95397 是一种选择性的Cdc25双特异性磷酸酶抑制剂。它抑制丝裂原活化蛋白激酶磷酸酶-1(MKP-1)，通过 MKP-1 和 ERK1 2 途径抑制结肠癌细胞的增殖并诱导细胞凋亡。

MPT0B214 is a novel and potent microtubule inhibitor with potential anticancer activity. MPT0B214 inhibited tubulin polymerization through strongly binding to the tubulin's colchicine-binding site and had cytotoxic activity in a variety of human tumor cell lines. After treatment with MPT0B214, KB cells were arrested in the G2-M phase before cell death occurred, which were associated with upregulation of cyclin B1, dephosphorylation of Cdc2, phosphorylation of Cdc25C and elevated expression of the mitotic marker MPM-2. Furthermore, the compound induced apoptotic cell death through mitochondria caspase 9-dependent pathway. Notably, several KB-derived multidrug-resistant cancer cell lines were also sensitive to MPT0B214 treatment. ( PLoS One. 2013;8(3):e58953).

M5N36 是一种有效的选择性Cdc25C 抑制剂，对 Cdc25A、Cdc25B、Cdc25C 的IC50值分别为 0.15、0.19、0.06 µM。M5N36 显示出抗增殖活性并增加 p-CDK1 和 p-CDK2 的表达。

PLK1-IN-9（Compound M2）是一种针对polo样激酶1 (PLK1) 的抑制剂，能有效抑制peptide 1010pT、cdc25c 和 PBIP 修饰的PLK 蛋白，其IC50值分别为1.6、0.8和1.4 μM。此外，PLK1-IN-9对HeLa、HL60、SNU387 499以及HepG2癌细胞表现出明显的抑制增殖效果，具有细胞毒性，并能诱导细胞凋亡（apoptosis）。在HepG2异种移植小鼠模型上，PLK1-IN-9同样有效抑制了肿瘤的生长。

Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2 M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. Rocaglaol can reduce tis